Partner Interview
Published September 24, 2024
Sartorius: Cultural Changes & COVID Disruptions
inpractise.com/articles/sartorius
Executive Bio
Former VP of Product Development at Sartorius
Interview Transcript
Disclaimer: This interview is for informational purposes only and should not be relied upon as a basis for investment decisions. In Practise is an independent publisher and all opinions expressed by guests are solely their own opinions and do not reflect the opinion of In Practise.
This is a snippet of the transcript.to get full access.
I just wanted to lay that out there with my background and how I'm thinking about the situation. Hopefully, that color helps inform our conversation and gives you a sense of the angle I'm coming from here.
Thank you very much for the introduction. Let me make two or three comments. What really happened with Sartorius is similar to what happened with Rome; they became arrogant. This led to a couple of wrong decisions, really wrong and egoistic decisions, from either René Fáber or Joachim Kreuzburg, which were against all logic, I must say. There was also a lot of restructuring, especially when we joined the DAX. These changes in the structure really destroyed an absolute winning team. We can go into more detail later if you like. The real problem was that we were so busy restructuring that we ended up destroying innovation. Almost no innovation was reaching the market, especially in the FMT - Fluid Management Technology - areas where I was responsible.
Free Sample of 50+ Interviews
Sign up to test our content quality with a free sample of 50+ interviews.
Or contact sales for full access
Related Content

Thermo Fisher Scientific Inc: Culture and Management
Former Director at Thermo Fisher Scientific

Danaher, Aldevron, Intangible & Goodwill Impairments

Porvair & Chromatography Lab Equipment: M&A Process & Culture
Former Senior Vice President Life Sciences at J.G. Finneran, Porvair plc

Thermo Fisher vs Danaher: Business Model and Competitive Positioning
Former Director, Corporate Strategy & Business Development at Thermo Fisher Scientific
© 2024 In Practise. All rights reserved. This material is for informational purposes only and should not be considered as investment advice.